Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $26.88 million. The enterprise value is $62.84 million.
Important Dates
The next confirmed earnings date is Thursday, March 12, 2026, before market open.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 44.72 million shares outstanding. The number of shares has increased by 2.01% in one year.
| Current Share Class | 44.72M |
| Shares Outstanding | 44.72M |
| Shares Change (YoY) | +2.01% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 5.54% |
| Owned by Institutions (%) | 28.10% |
| Float | 35.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 6.68 |
| PS Ratio | 0.30 |
| Forward PS | 0.29 |
| PB Ratio | 1.90 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.61 |
| P/OCF Ratio | 3.14 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 12.60, with an EV/FCF ratio of 8.45.
| EV / Earnings | n/a |
| EV / Sales | 0.72 |
| EV / EBITDA | 12.60 |
| EV / EBIT | n/a |
| EV / FCF | 8.45 |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of 3.04.
| Current Ratio | 0.81 |
| Quick Ratio | 0.35 |
| Debt / Equity | 3.04 |
| Debt / EBITDA | 5.87 |
| Debt / FCF | 5.75 |
| Interest Coverage | -0.40 |
Financial Efficiency
Return on equity (ROE) is -135.62% and return on invested capital (ROIC) is -2.69%.
| Return on Equity (ROE) | -135.62% |
| Return on Assets (ROA) | -0.82% |
| Return on Invested Capital (ROIC) | -2.69% |
| Return on Capital Employed (ROCE) | -5.80% |
| Weighted Average Cost of Capital (WACC) | 8.82% |
| Revenue Per Employee | $246,115 |
| Profits Per Employee | -$151,648 |
| Employee Count | 355 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 1.58 |
Taxes
In the past 12 months, HBIO has paid $243,000 in taxes.
| Income Tax | 243,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.26% in the last 52 weeks. The beta is 1.56, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | -58.26% |
| 50-Day Moving Average | 0.65 |
| 200-Day Moving Average | 0.51 |
| Relative Strength Index (RSI) | 54.09 |
| Average Volume (20 Days) | 546,326 |
Short Selling Information
The latest short interest is 434,784, so 0.97% of the outstanding shares have been sold short.
| Short Interest | 434,784 |
| Short Previous Month | 445,314 |
| Short % of Shares Out | 0.97% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 0.94 |
Income Statement
In the last 12 months, HBIO had revenue of $87.37 million and -$53.84 million in losses. Loss per share was -$1.22.
| Revenue | 87.37M |
| Gross Profit | 49.79M |
| Operating Income | -1.37M |
| Pretax Income | -53.59M |
| Net Income | -53.84M |
| EBITDA | 4.99M |
| EBIT | -1.37M |
| Loss Per Share | -$1.22 |
Full Income StatementBalance Sheet
The company has $6.82 million in cash and $42.79 million in debt, with a net cash position of -$35.97 million or -$0.80 per share.
| Cash & Cash Equivalents | 6.82M |
| Total Debt | 42.79M |
| Net Cash | -35.97M |
| Net Cash Per Share | -$0.80 |
| Equity (Book Value) | 14.07M |
| Book Value Per Share | 0.32 |
| Working Capital | -10.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $8.55 million and capital expenditures -$1.11 million, giving a free cash flow of $7.44 million.
| Operating Cash Flow | 8.55M |
| Capital Expenditures | -1.11M |
| Free Cash Flow | 7.44M |
| FCF Per Share | $0.17 |
Full Cash Flow StatementMargins
Gross margin is 56.99%, with operating and profit margins of -1.57% and -61.62%.
| Gross Margin | 56.99% |
| Operating Margin | -1.57% |
| Pretax Margin | -61.34% |
| Profit Margin | -61.62% |
| EBITDA Margin | 5.71% |
| EBIT Margin | -1.57% |
| FCF Margin | 8.52% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.01% |
| Shareholder Yield | -2.01% |
| Earnings Yield | -200.30% |
| FCF Yield | 27.68% |
Analyst Forecast
The average price target for HBIO is $2.50, which is 315.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.50 |
| Price Target Difference | 315.97% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HBIO has an Altman Z-Score of -2.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.44 |
| Piotroski F-Score | 3 |
